At the archive date, INCYTE CORP was expected to release its Q3 2026 10-Q filing on October 26, 2026. Last quarter: Incyte's Q2 FY2026 10-Q filing did not include XBRL income statement, balance sheet, cash flow, or ratio data, so this analysis is based solely on qualitative disclosures from the MD&A and Risk Factors sections, which highlight continued reliance on JAKAFI, pipeline advancement (INCA033989, tafasitamab, latarcibart), and the newly approved JAKAFI XR extended-release formulation.
EPS Estimate
$-3.46
Revenue Estimate
$1.51B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the INCY page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
In May 2026, the FDA approved JAKAFI XR (ruxolitinib) extended-release tablets for myelofibrosis, polycythemia vera, and steroid-refractory acute/chronic GVHD, broadening the hematology franchise's lead product line beyond the original JAKAFI formulation.
In January 2026, Incyte announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab and lenalidomide plus R-CHOP as first-line therapy for DLBCL, meeting both the primary endpoint (progression-free survival) and key secondary endpoint (event-free survival); global regulatory submissions were accepted in Q2 2026 with potential U.S. approval/launch anticipated in Q1 2027.
Following FDA Breakthrough Therapy designation granted in December 2025 for essential thrombocythemia (ET), a Phase 3 registrational study of INCA033989 in Type 1 and non-Type 1 mutCALR-positive ET patients was initiated in mid-2026, with a Phase 3 trial in myelofibrosis anticipated in the second half of 2026.
Revenue
$1.67B
+37.72% YoY
EPS (Diluted)
$2.81
+37.75% YoY
Operating Income
$697.9M
+31.60% YoY
Add INCY to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.